OverviewChartNewsTraderScreen

BNP Paribas Bonus Zert NVSEF 26.0.../  DE000PC75PF8  /

EUWAX
2024-05-15  9:36:01 AM Chg.- Bid10:00:40 PM Ask10:00:40 PM Underlying Strike price Expiration date Option type
84.18EUR - -
Bid Size: -		 -
Ask Size: -		 Novartis AG - - 2025-06-26 Call
GlobeNewswire 06-04 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 06-04 Nordicus Partners Corporation Appoints Peter Severin as Chairman Of The Board of Directors
GlobeNewswire 06-04 Bitterroot Bio Announces Appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as...
GlobeNewswire 05-29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
TeleTrader 05-02 Novartis to acquire Mariana Oncology for $1.7B
TeleTrader 04-23 Novartis up 5% on upbeat guidance, earnings
TeleTrader 04-23 Novartis EPS up 28% to $1.31 in Q1
GlobeNewswire 04-16 Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
TeleTrader 04-11 Novartis launches offer for Morphosys at €68 per share
TeleTrader 04-09 Novartis to reduce workforce by 680 in Product Development
GlobeNewswire 03-14 IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
TeleTrader 03-12 Germany clears Novartis' MorphoSys $2.9B deal
TeleTrader 02-05 Novartis to acquire MorphoSys for $2.9B
TeleTrader 01-31 Novartis net sales up 8% to $11.4B in Q4
GlobeNewswire 01-10 Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire 01-05 Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...
GlobeNewswire 01-02 Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Ad...
GlobeNewswire 2023-12-21 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire 2023-12-19 Related Sciences Adds 8 New Senior Advisors Including Former CEOs and Heads of R&D from Genentech, N...
GlobeNewswire 2023-12-11 Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and ...
GlobeNewswire 2023-12-08 Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broa...
GlobeNewswire 2023-12-06 Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement i...
TeleTrader 2023-11-28 Novartis expects 5% annual sales growth until 2027
GlobeNewswire 2023-11-20 Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
TeleTrader 2023-10-24 Novartis Q3 EPS up 20% to $0.73